Amarin Corp. (AMRN) option implied volatility elevated into sharp rally on release of patient study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Amgen (AMGN) Rumored as Potential Amarin (AMRN) Suitor
September 24, 2018 12:51 PM EDTChatter Amgen (NASDAQ: AMGN) could be looking to acquire Amarin Corp. (NASDAQ: AMRN), according to STAT's Adam Feuerstein (LINK)
Amarin Corporation (AMRN) PT Raised to $15 at Cantor Fitzgerald
September 24, 2018 10:05 AM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Amarin Corporation (NASDAQ: AMRN) to $15.00 (from $10.00) while maintaining a Overweight rating.
The raised PT is the result of Chen increasing her estimates for peak sales for Vascepa to $1.1 billion from $648.2 million.... More
Amarin (AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
September 24, 2018 8:39 AM EDTAmarin Corp. (NASDAQ: AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
... MoreAmarin Corp. (AMRN) Surges 278% on Positive Study Results
September 24, 2018 6:31 AM EDTAmarin Corp. (NASDAQ: AMRN) is surging 278% in pre-open trade after the company announced topline results from the Vascepa® cardiovascular (CV) outcomes trial, REDUCE-IT, a global... More
